Monte Rosa Therapeutics (GLUE) Operating Income Growth (3y) (2023 - 2026)
Monte Rosa Therapeutics (GLUE) Operating Income Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 55.96% |
| 10 | Monte Rosa Therapeutics | 2.29 Bn | 1.61 Bn | - | -13.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.46% |
| Dec 31, 2025 | -15.23% |
| Sep 30, 2025 | -5.15% |
| Jun 30, 2025 | 17.03% |
| Mar 31, 2025 | 56.21% |
| Dec 31, 2024 | 36.73% |
| Sep 30, 2024 | -10.11% |
| Jun 30, 2024 | -21.67% |
| Mar 31, 2024 | -44.83% |
| Dec 31, 2023 | -42.94% |
| Sep 30, 2023 | -79.56% |
| Jun 30, 2023 | -90.36% |